Prior exposure to biologics was associated with a decline in survival, with significantly larger reductions observed for ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

In recent years, treatment for psoriasis and psoriatic arthritis has improved drastically with the widespread usage of biologics. Biologics, also known as biologic response modifiers, are ...

The researchers found that 36.3% of patients had residual inflammation. (HealthDay News) — For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as ...

The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialized and marketed in Japan by Yoshindo Inc. Ustekinumab, a monoclonal antibody, is approved for the treatment ...

EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research ...

WEDNESDAY, May 21, 2025 (HealthDay News) -- For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by ...

Shares of Biocon Ltd. gained as much as 2% on Wednesday, May 21, after its subsidiary announced that its commercial partner in Japan launched the Ustekinumab BS Subcutaneous injection for the ...